For the CHRO, Head of Wellbeing, Chief People Officer or CEO who needs to justify the engagement to a finance director, a remuneration committee, or a partner group: the commercial case for prevention-led clinical work, stated honestly.
The business case for EPOCH-style engagement is not about insurance-style cost avoidance modelled across populations. It is about the preventive work that determines whether the senior people who carry your commercial weight retain the cognitive sharpness, recovery capacity and resilience the role requires across the years ahead.
Three commercial dimensions interact when you consider clinical-grade preventive work for senior teams. Each is measurable, each is meaningful, and each is currently underserved by conventional corporate wellbeing investment.
The senior teams in your organisation make consequential decisions under sustained cognitive load. The biology that supports decision-making under fatigue, sustained concentration across long days, recovery of cognitive function across consecutive demanding quarters, is metabolic and microbiome-influenced and architectural. It is also genuinely modifiable through clinical work begun early. Cognitive sharpness in the senior team is not a soft benefit; it is the underlying biology of commercial performance at the level where commercial performance is determined.
The forty-five to sixty cohort in any senior team typically includes people who feel reasonably well but are experiencing the early phases of underlying biology drift that conventional medical screening does not capture. The visible result is presenteeism: people present and working but operating below the underlying biology capacity the role requires. The published evidence base on presenteeism cost in senior workforces is substantial. Substrate-led clinical work addresses presenteeism early, rather than waiting for the clinical consequences that produce sickness absence.
Senior people increasingly think about the longer arc of their working life. The partner who is considering whether the next decade of partnership is sustainable. The executive considering whether the cognitive demands of the role are matched by the underlying biology they have. The leader thinking about post-retirement health and what the years after the working life will feel like. Organisations that engage with this question through prevention-led clinical work distinguish themselves as employers in ways that influence retention of the people who are most expensive to lose.
We are honest about what the business case is not. EPOCH engagement does not produce insurance-style cost avoidance numbers measured against actuarial baselines, because the preventive work operates early of the clinical events those numbers are derived from. We do not provide population-health dashboards or aggregate ROI calculators that promise specific percentage reductions in sickness absence or productivity gains. The clinical work is individual and the value is calibrated to the individual; aggregate claims at the population level would over-promise.
What we offer instead is a clinical engagement designed around the specific individuals in scope, with biological trajectory data that demonstrates what is changing for those individuals over time, and the integration with your wellbeing infrastructure that ensures the work compounds with the existing investment rather than competing with it.
Three questions worth asking when evaluating EPOCH against the alternative uses of the budget.
EPOCH operates a calibrated commercial framework rather than a packaged pricing schedule. The scoping conversation that establishes the clinical engagement framework also produces the commercial proposal. The framework is built around what the engagement will actually deliver: the cohort size, the engagement intensity, the brain imaging integration if clinically warranted, the duration, the reporting and governance arrangements.
Typical first-year engagement might involve a focus cohort of six to twelve participants with quarterly retest across the year. Framework allows expansion to additional cohorts in subsequent years based on the value demonstrated. The architecture protects you from large commitments before value is visible, and protects EPOCH from over-extending into engagements that are not the right fit.
The trademark filings and clinical IP remain proprietary to EPOCH METABOLIC. The institutional partner receives the clinical work, the longitudinal data for participants, and the integration with internal infrastructure, but does not acquire the methodology itself. This is standard for clinical practices working with institutional partners.
The initial scoping conversation establishes the organisational priorities, the cohort focus, the integration with existing infrastructure, and the commercial framework. Output is a clinical engagement framework document calibrated to your context.
Request a scoping conversation